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Kaposi's sarcoma (KS) is characterized by an abnormal
growth of blood vessels. KS was found mainly in older
men of Mediterranean or African origin (classic KS) or in
patients after organ transplantation (iatrogenic KS). How-
ever, in the early 1980s, an aggressive epidemic form,
linked to AIDS, was noticed and was one of the first clues
to the existence of HIV-1 pandemy. The link between KS
occurrence and HIV has raised multiple hypotheses. The
drastic reduction of KS after the introduction of HAART,
suggests HIV as a powerful co-factor for KS progression.
We and others have contributed to the elucidation of KS
cell nature and the possible involvement of extracellular
HIV Tat. Tat is proangiogenic and is a true promoter of KS
lesions acting as a VEGFR2 ligand both on KS and
endothelial cells, in addition Tat is able to bind and acti-
vate chemokine receptors on monocytes and granulocytes
causing a pro-inflammatory status. Evaluation of the
effects of extracellular Tat on KS cells by microarray anal-
ysis after 24 h of incubation shows an interesting cluster-
ing of gene products involved in signal transduction,
especially GTP-ase, Kinase and cAMP activity, confirming
that Tat acts extracellularly by ways that are probably
unrelated to its nuclear activity. KS occurrence is reduced
by HAART but still present and in Africa is one of the most
frequent oncologic disease. To find suitable drugs with
low toxic impact on KS patients, we have tested several
drugs and gene therapy approaches in in vivo models.
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